Physician
Gamut Medical Group PA
Gamut Medical Group PA was paid $5.98M by Medicaid between Jan 2018 and Dec 2024, across 58 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 17% of everything it billed.
33Billing provider infoGAMUT MEDICAL GROUP PA
EL PASO, TX 79904
EL PASO, TX 79904
33aNPI1790083012assigned 03/10/2011
33bProvider typeFamily Medicine Physician
28Total paid$5.98M
24GClaims223,682
24DCodes billed58
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Texas
Rank by total paid#13 of 1,204
Median peer was paid$31K
This provider vs. median194×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 392 | $9K | |
| 2019 | 944 | $18K | |
| 2020 | 30,298 | $651K | |
| 2021 | 72,607 | $1.84M | |
| 2022 | 53,372 | $1.55M | |
| 2023 | 35,174 | $1.01M | |
| 2024incomplete | 30,895 | $902K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 17% | 19,479 | 16,999 | $1.04M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 18,860 | 16,784 | $1.03M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 7.5% | 30,440 | 13,879 | $449K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.5% | 9,605 | 8,909 | $391K |
| S8301 | Infection control supplies, not otherwise specified | 6.2% | 13,523 | 11,307 | $373K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.8% | 3,698 | 3,618 | $348K |
| 86328 | 5.8% | 7,922 | 6,755 | $344K | |
| 94010 | 5.7% | 12,726 | 11,235 | $341K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.9% | 2,919 | 2,825 | $293K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.6% | 3,103 | 2,902 | $274K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.7% | 15,169 | 13,793 | $223K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.9% | 14,828 | 8,074 | $171K |
46 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.6% | 1,808 | $153K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.2% | 9,183 | $129K |
| 99429 | 1.5% | 2,562 | $91K | |
| 99406 | <1% | 5,432 | $57K | |
| 92551 | <1% | 5,671 | $53K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 468 | $43K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,874 | $35K |
| 87807 | <1% | 2,660 | $30K | |
| 94060 | <1% | 449 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,245 | $17K |
| 94760 | <1% | 10,677 | $17K | |
| 90461 | <1% | 2,077 | $13K | |
| 99000 | <1% | 1,030 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,537 | $8K |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | <1% | 292 | $7K |
| 99381 | <1% | 57 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 630 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 829 | $2K |
| 96160 | <1% | 885 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $1K |
| 96161 | <1% | 272 | $635.98 | |
| 81025 | <1% | 37 | $276.06 | |
| CP002 | <1% | 26 | $212.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 56 | $104.46 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 316 | $87.56 |
| 81002 | <1% | 12 | $32.35 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 15 | $32.00 |
| 90686 | <1% | 3,991 | $0.73 | |
| 90651 | <1% | 1,006 | $0.07 | |
| 90620 | <1% | 854 | $0.05 | |
| 90619 | <1% | 354 | $0.05 | |
| 90677 | <1% | 306 | $0.04 | |
| 90680 | 0% | 866 | $0.00 | |
| 90723 | 0% | 406 | $0.00 | |
| 36416 | 0% | 1,040 | $0.00 | |
| 90696 | 0% | 138 | $0.00 | |
| 90698 | 0% | 40 | $0.00 | |
| 90674 | 0% | 31 | $0.00 | |
| 90633 | 0% | 712 | $0.00 | |
| 90710 | 0% | 689 | $0.00 | |
| 90648 | 0% | 1,039 | $0.00 | |
| 90715 | 0% | 94 | $0.00 | |
| 90670 | 0% | 1,121 | $0.00 | |
| 90734 | 0% | 462 | $0.00 | |
| 90700 | 0% | 105 | $0.00 | |
| 90685 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialURQUIDI, ULYSSES (PRESIDENT)